Additionally, several inhibitors of the PI3K/Akt and PKC pathways have rendered promising results in vitro and in vivo, and may potentially have therapeutic application in CLL [5, 37, 38]. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.